Elanco Animal Health (NYSE:ELAN) Issues Q1 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.290-0.340 for the period, compared to the consensus estimate of 0.300. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.800-0.860 EPS.

Elanco Animal Health Trading Down 4.3 %

Shares of Elanco Animal Health stock traded down $0.48 during midday trading on Tuesday, reaching $10.64. 5,715,426 shares of the company’s stock traded hands, compared to its average volume of 4,694,626. The stock has a 50 day moving average of $11.78 and a 200-day moving average of $13.09. Elanco Animal Health has a 12 month low of $10.20 and a 12 month high of $18.80. The company has a market cap of $5.26 billion, a PE ratio of 26.58, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share. As a group, equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELAN has been the topic of several research reports. Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus lowered their price objective on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Morgan Stanley reduced their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 29th. Finally, UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Elanco Animal Health presently has an average rating of “Hold” and an average target price of $16.00.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.